ERAS

Erasca Inc

Add to Watchlist

Advanced Chart

1.710

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.760

Open

1.720

VWAP

1.71

Vol

677.43K

Mkt Cap

484.42M

Low

1.655

Amount

1.16M

EV/EBITDA(TTM)

Total Shares

272.82M

179.84M

EV/OCF(TTM)

P/S(TTM)

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.108

-62.85%

-0.112

+1.66%

-0.114

+3.94%

Estimates Revision

Stock Price

Go Up

+23.02%

In Past 3 Month

3 Analyst Rating

153.22% Upside

Wall Street analysts forecast ERAS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.33 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

153.22% Upside

Current: 1.710

Low

3.00

Averages

4.33

High

6.00

153.22% Upside

Current: 1.710

Low

3.00

Averages

4.33

High

6.00

Guggenheim

Michael Schmidt

Buy

downgrade

2025-05-14

Reason

Guggenheim

Michael Schmidt

Price Target

2025-05-14

downgrade

Buy

Reason

Guggenheim analyst Michael Schmidt lowered the firm's price target on Erasca to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q1 results and provided pipeline updates following a strategic announcement. The firm is updating its model to reflect Q1 results, removing naporafenib estimates from with potential partnership reflecting a source of potential upside to its estimates, and adding probability of success adjusted assumptions for ERAS-0015 and ERAS-4001, the analyst tells investors.

Raymond James

Laura Prendergast

Buy

Initiates

2025-03-26

Reason

Raymond James

Laura Prendergast

Price Target

2025-03-26

Initiates

Buy

Reason

HC Wainwright & Co.

Andres Maldonado

Strong Buy

Reiterates

2025-03-21

Reason

HC Wainwright & Co.

Andres Maldonado

Price Target

2025-03-21

Reiterates

Strong Buy

Reason

Goldman Sachs

Chris Shibutani

Strong Buy

Maintains

$3.5 → $3

2025-03-21

Reason

Goldman Sachs

Chris Shibutani

Price Target

$3.5 → $3

2025-03-21

Maintains

Strong Buy

Reason

Morgan Stanley

Jeffrey Hung

Buy

Initiates

2025-03-07

Reason

Morgan Stanley

Jeffrey Hung

Price Target

2025-03-07

Initiates

Buy

Reason

Morgan Stanley analyst Sean Laaman assumed coverage of Erasca with an Overweight rating and $4 price target. The firm sees potential upside from naporafenib and readthroughs in the (K)RAS space, the analyst tells investors in a research note. Morgan Stanley also says it is encouraged by the preclinical profiles of ERAS-0015 and ERAS-4001, but notes that it will take time for clinical data to be generated.

B of A Securities

Alec Stranahan

Hold

Strong Buy

Upgrades

2025-01-07

Reason

B of A Securities

Alec Stranahan

Price Target

2025-01-07

Upgrades

Hold

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Erasca Inc (ERAS.O) is -3.94, compared to its 5-year average forward P/E of -4.78. For a more detailed relative valuation and DCF analysis to assess Erasca Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.78

Current PE

-3.94

Overvalued PE

-2.25

Undervalued PE

-7.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.89

Current EV/EBITDA

-0.68

Overvalued EV/EBITDA

0.96

Undervalued EV/EBITDA

-6.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00